BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by BTIG Research

BioAge Labs (NASDAQ:BIOA) was upgraded by BTIG Research to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also recently weighed in on BIOA. Citigroup upped their price target on shares of BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Needham & Company LLC started coverage on shares of BioAge Labs in a research report on Friday, March 27th. They issued a “buy” rating and a $50.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Morgan Stanley set a $23.00 price target on shares of BioAge Labs in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.00.

BioAge Labs Price Performance

Shares of BIOA stock opened at $19.14 on Wednesday. The company has a market capitalization of $850.83 million, a P/E ratio of -7.97 and a beta of 0.99. The company’s 50-day simple moving average is $18.25 and its two-hundred day simple moving average is $15.73. BioAge Labs has a one year low of $3.67 and a one year high of $24.00.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. The business had revenue of $2.77 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. On average, research analysts expect that BioAge Labs will post -2.69 EPS for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of BIOA. Geode Capital Management LLC lifted its position in BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after acquiring an additional 171,426 shares during the last quarter. Walleye Capital LLC purchased a new stake in BioAge Labs during the second quarter valued at approximately $64,000. Marshall Wace LLP lifted its position in BioAge Labs by 324.7% during the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after acquiring an additional 173,388 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after acquiring an additional 5,976 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in BioAge Labs during the second quarter valued at approximately $182,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.